Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Mirikizumab (LY3074828) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Mirikizumab - IV
Drug: Mirikizumab - SC
Drug: Placebo - IV
Drug: Placebo - SC

First Posted Date: 2015-10-05

Last Posted Date: 2024-02-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 51

Registration Number: NCT02568423

Locations: 🇺🇸
WCCT Global, Cypress, California, United States

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

Phase 3

Completed

Conditions: Migraine Disorders

Interventions: Drug: Lasmiditan

First Posted Date: 2015-10-01

Last Posted Date: 2020-08-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2171

Registration Number: NCT02565186

Locations: 🇺🇸
Medical Affiliated Research Center, Huntsville, Alabama, United States
🇺🇸
East Valley Family Physicians, PLC, Chandler, Arizona, United States
🇺🇸
Fountain Hills Family Practice, P.C., Fountain Hills, Arizona, United States

and more 156 locations

A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors

Phase 1

Completed

Conditions: Refractory Tumor
Pediatric Solid Tumor
Recurrent Tumor
CNS Malignancies

Interventions: Drug: Ramucirumab

First Posted Date: 2015-09-30

Last Posted Date: 2021-08-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 29

Registration Number: NCT02564198

Locations: 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
Texas Childrens Hospital, Houston, Texas, United States
🇺🇸
Seattle Children's Hospital Research Foundation, Seattle, Washington, United States

and more 18 locations

A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: LY3154207

First Posted Date: 2015-09-29

Last Posted Date: 2017-03-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT02562768

Locations: 🇺🇸
Parexel International LLC, Glendale, California, United States
🇺🇸
Compass Research, The Villages, Florida, United States

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Ustekinumab
Drug: Ixekizumab
Drug: Placebo

First Posted Date: 2015-09-28

Last Posted Date: 2020-06-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 302

Registration Number: NCT02561806

Locations: 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Toronto, Canada
🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salford, United Kingdom

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Human regular U-500 insulin (CSII)
Drug: Human regular U-500 insulin (MDI)

First Posted Date: 2015-09-25

Last Posted Date: 2020-05-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 420

Registration Number: NCT02561078

Locations: 🇵🇷
Endocrine Lipid Diabetes Research Institute, Ponce, Puerto Rico
🇵🇷
American Telemedicine Center, San Juan, Puerto Rico
🇵🇷
Martha Gomez Cuellar M.D., San Juan, Puerto Rico

and more 51 locations

A Study of [¹⁴C]-LY3202626 in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [¹⁴C]-LY3202626

First Posted Date: 2015-09-21

Last Posted Date: 2021-04-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 6

Registration Number: NCT02555449

Locations: 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Neoplasms

Interventions: Drug: Prexasertib
Drug: Cisplatin
Drug: Cetuximab
Radiation: Intensity Modulated Radiation Therapy

First Posted Date: 2015-09-21

Last Posted Date: 2019-02-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 70

Registration Number: NCT02555644

Locations: 🇺🇸
University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States
🇫🇷
Gustave Roussy, Villejuif Cedex, France
🇫🇷
Centre Leon Berard, Lyon, France

and more 1 locations

A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ixekizumab
Drug: Boostrix®
Drug: Pneumovax®23

First Posted Date: 2015-09-07

Last Posted Date: 2017-01-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 84

Registration Number: NCT02543918

Locations: 🇺🇸
Covance, Dallas, Texas, United States

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2

Completed

Conditions: Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Ramucirumab
Drug: Placebo
Drug: S-1
Drug: Oxaliplatin
Drug: Paclitaxel

First Posted Date: 2015-09-02

Last Posted Date: 2022-03-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 191

Registration Number: NCT02539225

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Toyonaka, Japan
🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

Home Terms & Conditions Privacy Policy